Cover Image
市場調查報告書

Apeiron Biologics AG:產品平台分析

APEIRON Biologics AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251641
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
Apeiron Biologics AG:產品平台分析 APEIRON Biologics AG - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 37 Pages
簡介

Apeiron Biologics AG 是開發各種癌症和相關疾病治療的生物學及免疫學解決方案的生物科技企業。該公司的產品有作為兒童癌症常見的神經母細胞瘤的治療藥。

本報告提供Apeiron Biologics AG 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

APEIRON Biologics AG的基本資料

  • APEIRON Biologics AG概要
  • 主要資訊
  • 企業資料

Apeiron Biologics AG:R&D概要

  • 主要的治療範圍

Apeiron Biologics AG:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Apeiron Biologics AG:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Apeiron Biologics AG:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

Apeiron Biologics AG:藥物簡介

  • APN-201
  • APN-311
  • APN-301
  • APN-401
  • APN-411
  • Drugs for Cancer and Related Conditions

Apeiron Biologics AG:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Apeiron Biologics AG:最近的開發平台趨勢

Apeiron Biologics AG:暫停中的計劃

Apeiron Biologics AG:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06924CDB

Summary

Global Markets Direct's, 'APEIRON Biologics AG - Product Pipeline Review - 2015', provides an overview of the APEIRON Biologics AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of APEIRON Biologics AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of APEIRON Biologics AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of APEIRON Biologics AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the APEIRON Biologics AG's pipeline products

Reasons to buy

  • Evaluate APEIRON Biologics AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of APEIRON Biologics AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the APEIRON Biologics AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of APEIRON Biologics AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of APEIRON Biologics AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of APEIRON Biologics AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • APEIRON Biologics AG Snapshot
    • APEIRON Biologics AG Overview
    • Key Information
    • Key Facts
  • APEIRON Biologics AG - Research and Development Overview
    • Key Therapeutic Areas
  • APEIRON Biologics AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • APEIRON Biologics AG - Pipeline Products Glance
    • APEIRON Biologics AG - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • APEIRON Biologics AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • APEIRON Biologics AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • APEIRON Biologics AG - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • APEIRON Biologics AG - Drug Profiles
    • APN-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APN-311
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APN-301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APN-401
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APN-411
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Cancer and Related Conditions
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • APEIRON Biologics AG - Pipeline Analysis
    • APEIRON Biologics AG - Pipeline Products by Target
    • APEIRON Biologics AG - Pipeline Products by Route of Administration
    • APEIRON Biologics AG - Pipeline Products by Molecule Type
    • APEIRON Biologics AG - Pipeline Products by Mechanism of Action
  • APEIRON Biologics AG - Recent Pipeline Updates
  • APEIRON Biologics AG - Dormant Projects
  • APEIRON Biologics AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • APEIRON Biologics AG, Key Information
  • APEIRON Biologics AG, Key Facts
  • APEIRON Biologics AG - Pipeline by Indication, 2015
  • APEIRON Biologics AG - Pipeline by Stage of Development, 2015
  • APEIRON Biologics AG - Monotherapy Products in Pipeline, 2015
  • APEIRON Biologics AG - Out-Licensed Products in Pipeline, 2015
  • APEIRON Biologics AG - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • APEIRON Biologics AG - Phase III, 2015
  • APEIRON Biologics AG - Phase II, 2015
  • APEIRON Biologics AG - Phase I, 2015
  • APEIRON Biologics AG - Preclinical, 2015
  • APEIRON Biologics AG - Discovery, 2015
  • APEIRON Biologics AG - Unknown, 2015
  • APEIRON Biologics AG - Pipeline by Target, 2015
  • APEIRON Biologics AG - Pipeline by Route of Administration, 2015
  • APEIRON Biologics AG - Pipeline by Molecule Type, 2015
  • APEIRON Biologics AG - Pipeline Products by Mechanism of Action, 2015
  • APEIRON Biologics AG - Recent Pipeline Updates, 2015
  • APEIRON Biologics AG - Dormant Developmental Projects,2015

List of Figures

  • APEIRON Biologics AG - Pipeline by Top 10 Indication, 2015
  • APEIRON Biologics AG - Pipeline by Stage of Development, 2015
  • APEIRON Biologics AG - Monotherapy Products in Pipeline, 2015
  • APEIRON Biologics AG - Pipeline by Top 10 Target, 2015
  • APEIRON Biologics AG - Pipeline by Top 10 Route of Administration, 2015
  • APEIRON Biologics AG - Pipeline by Top 10 Molecule Type, 2015
  • APEIRON Biologics AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top